Scoop has an Ethical Paywall
Eisai Commences Business Activities At New Pharma Sales Subsidiary In Israel
Eisai Co., Ltd. announced today that fully-fledged operations and business activities have begun at Eisai Israel Ltd., a pharmaceutical sales subsidiary recently established in Tel Aviv in the State of Israel (Israel). Eisai Israel is a wholly-owned subsidiary of Eisai's European regional headquarters, Eisai Europe Ltd.
Israel's pharmaceutical market reached 5.3 billion USD in 2021.1 The compound annual growth rate of the Israel pharmaceutical market from 2018 to 2021 was +8.56%1 and the market is expected to continue to grow steadily, with a high penetration rate of innovative medicines.
In 2011, Eisai Europe started business in Israel marketing and selling Eisai products through local distribution partners, and mainly marketed Lenvima, Halaven, Fycompa and Inovelon. Eisai Israel was established in August 2021, and in January 2023, became the marketing authorization holder of the Eisai products in Israel. Eisai Israel will now perform sales and marketing activities for these products. The company plans to launch its other global brands in the future.
With the commencement of operations at Eisai Israel, Eisai aims to utilize its own drug sales system in Israel, deliver innovative new drugs to more patients in Israel as quickly as possible, and contribute to improving the benefits of patients and their families.
Stats NZ: Petrol And Diesel Prices Continue To Rise In April 2026
Priority one: Regional Deal Strengthens Confidence In The Western Bay Of Plenty
REINZ: Buyer Activity Softens As Living Costs Remain A Consideration Across Key Regions
Better Taxes for a Better Future: Tax Policy Welcome Contribution, But Missed Opportunity To Tackle Wealth Inequality
Google Threat Intelligence Group - GTIG: Google Threat Report Warns AI-Driven Cyber Operations Are Scaling Across Global Threat Landscape
Commerce Commission: Baseline Research Report On The State Of Competition In New Zealand
